Tobacco Products Pharmacology Study

The Tobacco Products Pharmacology Study is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle awarded by the Department of Health and Human Services Food and Drug Administration (HHS FDA) to conduct comprehensive scientific research on tobacco products. The primary objective of this contract is to evaluate the impact of various tobacco products on human behavior, pharmacology, and physiological responses through a series of clinical studies. These studies aim to assess critical aspects such as product dependence, craving, withdrawal, use behavior, harm perception, and biomarkers of exposure across different tobacco product types including smokeless tobacco, mentholated products, and cigars.

The task orders under this IDIQ have been predominantly awarded to research organizations like Lovelace Biomedical Research Institute and Battelle Memorial Institute, with typical contract values ranging from approximately $782,000 to $1,835,000. The delivery orders consistently focus on specific tobacco product investigations, such as studying nicotine pharmacokinetics, subjective effects of mentholated smokeless tobacco, and assessing tobacco product pharmacology in human subjects. Each task order is structured as a firm fixed-price contract, with no specific set-aside designations, and completion dates typically spanning two to three years. The research appears to involve multiple subcontractors, including academic institutions like Virginia Commonwealth University and the University of California, San Francisco, to provide specialized analytical and clinical research capabilities.